

Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>.

Manuscript DOI: https://doi.org/10.2337/[insert manuscript submission number] (Example, https://doi.org/10.2337/db18-1234)	
Title: Human islet microRNA-200c is elevated in type 2 diabetes and targets the transcription factor ETV5 to reduce insulin secretion	
Author list: Jones K. Ofori, Alexandros Karagiannopoulos, Mototsugu Nagao, Efraim Westholm, Shaima Ramadan, Anna Wendt, Jonathan LS Esguerra and Lena Eliasson	
Corresponding author: Lena Eliasson	Email address: lena.eliasson@med.lu.se

Islet preparation	9	10	11	12	13	14	15	16 ^a
MANDATORY INFORMATION								
Unique identifier	ND_9	ND_10	ND_11	ND_12	ND_13	ND_14	ND_15	ND_16
Donor age (years)	40	53	73	51	57	32	67	57
Donor sex (M/F)	M	F	M	M	M	M	F	M
Donor BMI (kg/m ²)	24.7	25.7	26.2	24.9	29.9	24.5	23.9	23.7

Donor HbA _{1c} or other measure of blood glucose control	5.5	5.5	5.4	5.4	5.4	5.3	5.3	5.3
Origin/source of islets ^b	Nordic Network for Islet Transplantation	Nordic Network for Islet Transplantation	Nordic Network for Islet Transplantation	Nordic Network for Islet Transplantation	Nordic Network for Islet Transplantation	Nordic Network for Islet Transplantation	Nordic Network for Islet Transplantation	Nordic Network for Islet Transplantation
Islet isolation centre	Islet isolation facility in Uppsala, Sweden	Islet isolation facility in Uppsala, Sweden	Islet isolation facility in Uppsala, Sweden	Islet isolation facility in Uppsala, Sweden	Islet isolation facility in Uppsala, Sweden	Islet isolation facility in Uppsala, Sweden	Islet isolation facility in Uppsala, Sweden	Islet isolation facility in Uppsala, Sweden
Donor history of diabetes? Yes/No	No	No	No	No	No	No	No	No
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)								
Glucose-lowering therapy at time of death ^c								

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								

Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Yes/No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results